Plasma Neutrophil Gelatinase-Associated Lipocalin and Interleukin-9 as Acute Kidney Injury Predictors After Coronary Artery Bypass Graft Following Cardiopulmonary Bypass

Ghuraba Adisurya, Kun Arifi Abbas*, Nancy Margarita Rehatta and Hardiono

Anesthesiology and Intensive Care Department, Faculty of Medicine Universitas Airlangga, Surabaya 60286 Indonesia

*Corresponding author details: Kun Arifi Abbas; kunarifi@gmail.com

ABSTRACT

Background: Acute Kidney Injury (AKI) incidence of postoperative Coronary Artery Bypass Graft (CABG) with Cardiopulmonary Bypass (CPB) at Dr. Soetomo General Academic Hospital reached 69.8%, higher than the global average of 5-20%. Predictors of postoperative AKI are needed; potential biomarkers include plasma Neutrophil Gelatinase-Associated Lipocalin (NGAL) and Interleukin-9 (IL-9). This study aims to analyze the predictive ability of these two biomarkers.

Methods: This is a prospective observational study in CABG patients with CPB without previous renal abnormalities at Dr. Soetomo in September-December 2020. Examination of plasma NGAL and IL-9 was carried out before, during, and after the CPB procedure.

Results: 21 patients were included in the study, 17 people (81.0%) were male. AKI experienced 14 people (66.7%); 3 people (14.3%) died. Patients without AKI had higher plasma NGAL results at preinduction (17.9±10.3 vs 17.1±15.5), durante (20.5±8.2 vs 16.9±7.8), and early ICU (24.0±8.6 vs 22.9±10.4). Patients with AKI had higher plasma IL-9 results at preinduction (63.3±23.2 vs 55.7±15.8), durante (45.2±11.0 vs 44.2±9.2), and early ICU (49.6±11.3 vs 46.2±15.6). There was no statistically significant relationship between plasma NGAL and IL-9 results.

Conclusion: Most CABG patients undergoing CPB have AKI. Patients without AKI had higher NGAL results and lower IL-9 in plasma. Statistically, neither of them can be used as predictive biomarkers of the incidence of AKI so far.

Keywords: NGAL; IL-9; Plasma; AKI; CPB; CABG

INTRODUCTION

The Coronary Artery Bypass Graft (CABG) procedure with the Cardiopulmonary Bypass (CPB) technique has a major drawback, namely systemic ischemia in which one of the target organs is the kidney(Setiari et al., 2017). The presence of hypoperfusion, ischemic-reperfusion injury, neurohumoral activation, activation of the inflammatory response, oxidative stress, nephrotoxins, coagulation disorders, and mechanical factors lead to decreased kidney function and eventually Acute Kidney Injury (AKI) occurs (Prabhu et al., 2010); (Wang & Bellomo, 2017). There are several conditions associated with the incidence of postoperative AKI CABG with CPB, namely old age and female gender, preoperative cardiac dysfunction, emergency surgery, peripheral arterial disease, re-intervention, diabetes requiring insulin, intraoperative use of aprotinin, suffering from obstructive pulmonary disease. chronic obstructive pulmonary disease (COPD), and preoperative renal dysfunction (Vives et al., 2019).

In the United States, the number of CABG operations is estimated at 200 thousand per year (Melly et al., 2018). Meanwhile in Indonesia, there is no national data that conveys the epidemiological data yet. However, it is known that at Dr. Soetomo General Academic Hospital Surabaya, Indonesia, the CABG procedure in 2018 and 2019 has reached 82 and 64 times. It is estimated that about 5-20% of CABG operations using a CPB machine will have postoperative AKI complications and this will increase the risk of mortality by > 60%(Prabhu et al., 2010). Searching in our preliminary study about the medical records of Dr. Soetomo General Academic Hospital Surabaya, Indonesia, showed that the incidence of AKI after CABG surgery using a CPB machine in 2019 reached 63.8%. Thus, the identification of renal dysfunction before surgery is important to predict the occurrence of AKI after surgery (Wang & Bellomo, 2017).

Neutrophil gelatinase-associated lipocalin is a potent renal troponin consisting of eight b-strains forming a b-barrel calyx for binding and transporting low-molecular chemicals (Soni et al., 2010). NGAL levels are known to increase early in the course of AKI. This was conveyed by a review study in 2017 which stated that the use of NGAL combined with other kidney function assessments could be useful for early detection of AKI related to heart surgery(Vandenbergh et al., 2017). Biomarker markers have a high predictor value in post-cardiac surgery AKI and can be used for early detection where it will appear in plasma within hours after kidney damage occurs so it is more sensitive than serum creatinine and urine production (O’Neal JB, et al. 2016; Fadel FI, et al. 2012; Antonucci E, et al. 2014; Mosa OF. 2018).
Another biomarker that is also thought to be used to predict the occurrence of AKI is interleukin-9 (IL-9). Interleukin-9 is a pleiotropic inflammatory cytokine produced by various inflammatory cells, such as mast cells, natural killer cells, T-helper cells, T-regulatory cells, and others. These cytokines primarily function as regulators of the activity of hematopoietic cells (Noelle & Nowak, 2010). IL-9 levels are known to increase during monocyte activation due to the inflammatory response by TNF- and IL-18 in a cohort study showing that IL-9 levels can be used to differentiate the diagnosis of acute interstitial nephritis from the diagnosis of acute kidney injury (Moledina & Parikh, 2019). With this description, this study was designed to analyze levels of neutrophil gelatinsase-associated lipocalin and plasma interleukin-9 which were used as predictors of the incidence of AKI after coronary artery bypass graft surgery with cardiopulmonary bypass.

**METHOD**

This study is an observational analytic study with a prospective longitudinal design used to analyze the role of plasma NGAL and IL-9 levels as predictors of AKI after CAGB surgery with CPB. Prospective longitudinal means that this study takes data over a certain period of time, over a long period of time, on future findings.

The research begins with the submission of research proposals, ethical management, and licensing arrangements at the research location. After all, three are completed, the research continues with the selection of samples from the population. Then, IL-9 and NGAL were examined on all research samples. Researchers then recorded the incidence of AKI. The study concludes with a presentation, evaluation, and publication.

The sample of this study were patients who underwent CAGB surgery with the CPB technique at Dr. Soetomo General Academic Hospital Surabaya, Indonesia, during September-December 2020 who met the inclusion and exclusion criteria. This research was conducted at the Central Surgical Installation, Integrated Cardiac Service Center, nursing ward, and ICU Dr. Soetomo General Academic Hospital Surabaya, Indonesia, during September-December 2020.

**RESULT**

This research was conducted in Dr. Soetomo General Academic Hospital Surabaya, Indonesia. A total of 21 patients were included in this study. The inclusion criteria of this study were all patients undergoing CPB at Dr. Soetomo General Academic Hospital Surabaya, Indonesia, with complete examination data.

The sample of this study was dominated by men with a total of 17 (81.0%). The most common comorbidities were hypertension and a combination of hypertension and diabetes mellitus, namely 4 samples (19%) and uncontrolled comorbidities with 18 (85.7%). The majority of patients undergoing CPB had AKI with a total of 15 (71.4%). Outcome of the patients obtained as many as 3 samples (14.3%) with the survivors as many as 18 samples (85.7%). Most of the KRS samples on day 5 and 7 were 5 samples (23.8%) followed by day 6 and 3 samples died (14.3%).

The basic characteristics of the study using a numerical scale where the mean ± SD of the patient’s age was 58.7 ± 8.6 years, the patient’s BMI was 24.5 ± 3.0, the length of ICU stay was 2.6 ± 1.0 days, the length of action was 413.8 ± 72.2 minutes, ejection fraction (%) 58 ± 9.69, and total post ICU 3.64 ± 1.05.

The results of the Shapiro-Wilk test showed that only NGAL and IL-9 pre CPB data in the AKI group and early ICU IL-9 data in the group without AKI were not normally distributed (p < 0.05), while the NGAL and IL-9 data during CPB and Other early ICUs were normally distributed. Differences in NGAL and IL-9 pre CPB and IL-9 early ICU between the AKI and without AKI groups were analyzed using the Mann Whitney test, while the differences in NGAL and IL-9 during CPB and early ICU NGAL between the AKI and without AKI groups were analyzed using the T test. 2 free samples.

**TABLE 1:** The test results of the normal distribution of NGAL and IL-9 deltas data

<table>
<thead>
<tr>
<th>Biomarker</th>
<th>P Value</th>
<th>AKI (n = 14)</th>
<th>Non-AKI (n = 7)</th>
</tr>
</thead>
<tbody>
<tr>
<td>NGAL</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Pre CPB</td>
<td>0.003</td>
<td>0.582</td>
<td></td>
</tr>
<tr>
<td>Durante CPB</td>
<td>0.389</td>
<td>0.288</td>
<td></td>
</tr>
<tr>
<td>Early ICU</td>
<td>0.445</td>
<td>0.178</td>
<td></td>
</tr>
<tr>
<td>IL-9</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Pre CPB</td>
<td>0.027</td>
<td>0.680</td>
<td></td>
</tr>
<tr>
<td>Durante CPB</td>
<td>0.990</td>
<td>0.339</td>
<td></td>
</tr>
<tr>
<td>Early ICU</td>
<td>0.311</td>
<td>0.019</td>
<td></td>
</tr>
</tbody>
</table>

Based on Table 1, the results of the Shapiro-Wilk test show that only NGAL and IL-9 pre CPB data in the AKI group and early ICU IL-9 data in the group without AKI were not normally distributed (p < 0.05). Meanwhile, data on NGAL and IL-9 during CPB and other early ICUs were normally distributed. Differences in NGAL and IL-9 pre CPB and IL-9 early ICU between the AKI and without AKI groups were analyzed using the Mann Whitney test, while the differences in NGAL and IL-9 during CPB and early ICU NGAL between the AKI and without AKI groups were analyzed using the T test. 2 free samples.

**Effect of NGAL on the incidence of AKI after CPB**

Table 2 below is compiled to show the analysis of the relationship between Neutrophil Gelatinsase-Associated Lipocalin and the incidence of AKI in patients with CPB.

Available Online at www.ijscia.com | Volume 2 | Issue 4 | Jul-Sep 2021
Statistically significant relationships were not found in the those with AKI than those without (3.5 ± 5.3 vs. 6.0 ± 10.6). There was no statistically significant relationship between preinduction NGAL (p-value 0.900), durante (p-value 0.343) and early ICU (p-value 0.816).

**TABLE 2: The relationship between Neutrophil Gelatinase-Associated Lipocalin and the incidence of AKI.**

<table>
<thead>
<tr>
<th>AKI Incidence (Mean ± SD)</th>
<th>Yes</th>
<th>No</th>
<th>p-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>NGAL Preinduction</td>
<td>17.1 ± 15.5</td>
<td>17.9 ± 10.3</td>
<td>0.900*</td>
</tr>
<tr>
<td>NGAL Durante</td>
<td>16.9 ± 7.8</td>
<td>20.5 ± 8.2</td>
<td>0.343*</td>
</tr>
<tr>
<td>NGAL Early ICU</td>
<td>22.9 ± 10.4</td>
<td>24.0 ± 8.6</td>
<td>0.816*</td>
</tr>
</tbody>
</table>

*: Mann Whitney, #: T-Test

Table 2 shows that patients without AKI had higher NGAL than those with AKI both at preinduction (17.9 ± 10.3 vs. 17.1 ± 15.5), durante (20.5 ± 82 vs. 16.9 ± 7.8) and early ICU (24.0 ± 8.6 vs. 22.9 ± 10.4). There was no statistically significant relationship between preinduction NGAL (p-value 0.900), durante (p-value 0.343) and early ICU (p-value 0.816).

**Effect of IL-9 on the Incidence of Post-CPB AKI**

Table 3 below shows an analysis of the relationship between IL-9 and the incidence of AKI in patients with CPB.

**TABLE 3: The relationship between IL-9 and the incidence of AKI**

<table>
<thead>
<tr>
<th>AKI Incident (Mean ± SD)</th>
<th>Yes</th>
<th>No</th>
<th>p-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>IL-9 Preinduction</td>
<td>63.3 ± 23.2</td>
<td>55.7 ± 15.8</td>
<td>0.444*</td>
</tr>
<tr>
<td>IL-9 Durante</td>
<td>45.2 ± 11.0</td>
<td>44.2 ± 9.2</td>
<td>0.838*</td>
</tr>
<tr>
<td>IL-9 Early ICU</td>
<td>49.6 ± 11.3</td>
<td>46.2 ± 15.6</td>
<td>0.351*</td>
</tr>
</tbody>
</table>

*: Mann Whitney, #: T-Test

Table 3 shows that patients with AKI had higher IL-9 than those without AKI either at preinduction (63.3 ± 23.2 vs. 55.7 ± 15.8), durante (45.2 ± 11.0 vs. 44.2 ± 9.2) and early ICU (49.6 ± 11.3 vs. 46.2 ± 15.6). There was no statistically significant relationship between IL-9 preinduction (p-value 0.444), durante (p-value 0.838), and early ICU (p-value 0.351).

**Effect of Delta NGAL with Post-CPB AKI Incidence**

Table 4 below shows an analysis of the relationship between delta NGAL and the incidence of AKI in patients with CPB.

**TABLE 4: The relationship between the NGAL delta and the incidence of AKI**

<table>
<thead>
<tr>
<th>AKI Incident (Mean ± SD)</th>
<th>Yes</th>
<th>No</th>
<th>p-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Delta NGAL Durante- Preinduction</td>
<td>-0.2 ± 16.0</td>
<td>2.6 ± 7.4</td>
<td>0.657*</td>
</tr>
<tr>
<td>Delta NGAL Early ICU-Preinduction</td>
<td>5.9 ± 15.3</td>
<td>6.1 ± 11.0</td>
<td>0.968*</td>
</tr>
<tr>
<td>Delta NGAL Early ICU-Durante</td>
<td>6.0 ± 10.6</td>
<td>3.5 ± 5.3</td>
<td>0.546*</td>
</tr>
</tbody>
</table>

*: Mann Whitney, #: T-Test

Table 4 shows that patients without AKI had higher NGAL deltas than those with AKI during preinduction (2.6 ± 7.4 vs -0.2 ± 16.0) and early ICU-preinduction (6.1 ± 11.0 vs. 5.9 ± 15.3), while in early ICU-durante it was higher in those with AKI than those without (3.5 ± 5.3 vs. 6.0 ± 10.6). Statistically significant relationships were not found in the NGAL delta during-preinduction (p-value 0.657), early ICU-preinduction (p-value 0.968) and early ICU-durante (p-value 0.546).

**Effect of Delta IL-9 with Post-CPB A AKI Incidence**

Table 5 below shows an analysis of the relationship between delta IL-9 and the incidence of AKI in patients with CPB.

**TABLE 5: Relationship between delta IL-9 and the incidence of AKI**

<table>
<thead>
<tr>
<th>AKI Incident (Mean ± SD)</th>
<th>Yes</th>
<th>No</th>
<th>p-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Delta IL-9 Durante-Preinduction</td>
<td>-18.1 ± 25.8</td>
<td>-11.5 ± 15.8</td>
<td>0.518*</td>
</tr>
<tr>
<td>Delta IL-9 Early ICU-Preinduction</td>
<td>-13.7 ± 19.7</td>
<td>-9.4 ± 19.0</td>
<td>0.622*</td>
</tr>
<tr>
<td>Delta IL-9 Early ICU-Durante</td>
<td>4.4 ± 11.9</td>
<td>2.05 ± 16.7</td>
<td>0.692*</td>
</tr>
</tbody>
</table>

*: Mann Whitney, #: T-Test
Acute kidney injury (AKI) is estimated to occur in 5% of hospitalized patients and as many as two thirds of intensive care unit patients. Early detection of AKI can facilitate timely intervention before the injury becomes irreversible in order to limit morbidity and mortality. The diagnosis of AKI is based on changes in serum creatinine, which may not manifest for several hours after the initial disturbance (Gabbard W et al., 2010; Kasper; Denis L; et al, 2018).

Neutrophil Gelatinase-Associated Lipocalin is a small (i.e., 25 kDa) protein that is part of the lipocalin family, originally discovered in 2003 by genome analysis of kidney genes induced in response to experimental AKI in animals. Neutrophil Gelatinase-Associated Lipocalin is primarily expressed by neutrophils and proximal renal tubules, while it can also be produced at much lower levels in prostate and respiratory and gastrointestinal epithelium (Dent CL et al., 2007).

Serum creatinine is an inadequate marker for early detection of AKI. First, more than 50% of renal function must be lost before an increase in serum creatinine is detected. Second, serum creatinine does not accurately reflect renal function until a steady state is reached and it may take several days after kidney damage. Animal studies have shown that AKI can be prevented and/or treated using several maneuvers, this should be done very early after kidney damage and long before an increase in serum creatinine is apparent. Monitoring of plasma NGAL levels has the potential to provide early warning to critical care providers (Dent CL et al., 2007).

Neutrophil Gelatinase-Associated Lipocalin can already be used as a stress marker because it is widely expressed in cells after infection, inflammation, ischemia, or neoplastic transformation. Its small size and resistance to degradation make NGAL easily detectable in both blood and urine. The potential use of NGAL as a biomarker of AKI has been recognized because it is one of the earliest and most rapidly induced genes in the kidney after ischemia or nephrotoxicity. Injury to animal models (Antonucci E et al., 2014).

This study showed that patients without AKI had higher NGAL than those with AKI both at preinduction (17.9 ± 10.3 vs. 17.1 ± 15.5), durante (20.5 ± 8.2 vs. 16.9 ± 7.8) and early ICU (24.0 ± 8.6 vs. 22.9 ± 10.4). There was no statistically significant relationship between preinduction NGAL (p-value 0.900); durante (p-value 0.343) and early ICU (p-value 0.816). Meanwhile, in the calculation of changes or NGAL deltas, patients who did not experience AKI were higher than those with AKI in Pre (3.5 ± 7.6 vs. -0.3 ± 15.4) and durante (7.6 ± 11.2 vs. 5.3 ± 14.9), whereas in the early ICU it was higher in those with AKI than those without (5.6 ± 10.3 vs. 4.0 ± 5.6). Statistically significant relationships were not found in the NGAL delta durante-preinduction (p-value 0.657), early ICU-preinduction (p-value 0.968) and early ICU-durate (p-value 0.546).

Postoperative Neutrophil Gelatinase-Associated Lipocalin best identifies AKI in patients with a glomerular filtration rate (GFR) of 90 to 120 ml/min. Patients with baseline GFR <60 ml/min generally have a urinary NGAL that does not differ between those with and without AKI (Bennett M et al, 2008).

Renal impairment during extracorporeal circulation can be caused by decreased renal perfusion, so that an increase in NGAL expression is expected to occur in the intraoperative period or during surgery in this study. The significant decrease in uNGAL at baseline CPB suggests that the condition may be due to hemodilution at induction of anesthesia. After 2 hours of using CPB and at the end of the operation and after that a significant improvement of uNGAL was seen (Friedrich MG et al., 2017).
Relationship between IL-9 and AKI in CPB Patients

Inflammation is a rapid, intense, and non-specific systemic reaction to tissue injury involving cellular and humoral mechanisms. During cardiac surgery, a strong general inflammatory response is activated by surgical trauma, blood loss, transfusion, and temperature changes. This response has a significant clinical impact. Inflammatory changes in the outcome of the procedure are high priority targets for the development of treatment and prevention strategies (Aljure OD & Fabbro M, 2019).

Changes in the time course, magnitude, or pattern of cytokine release after CPB may contribute to abnormalities in the inflammatory response to cardiac surgery. These patterns are important to understand if yield metrics are to be improved. During CPB, several inflammatory mechanisms are triggered. Initially, contact of blood with foreign surfaces of the CPB circuit activates the coagulation cascade and the complement system. Complement factors and their degradation products can exert immunomodulatory effects, induce the synthesis of proinflammatory cytokines, strengthen systemic responses responses (Aljure OD & Fabbro M, 2019).

The IL-9 gene is another inflammatory mediator located on chromosome 5. IL-9 was first described as a growth factor secreted by Th2 cells. Th17, regulatory T cells (Treg), TGF-b, and IL-4 also increase IL-9 secretion. IL-9 has various functions in immune and inflammatory responses by passing through the C family of receptors on target cells. These cytokines stimulate cell differentiation and prevent apoptosis (Jouybar R et al., 2020).

IL-9 can act as a positive and negative regulator of the immune response. In other words, IL-9 has different effects on disease progression. Melatonin is an N-acetyl-5-methoxy-tryptamine chemical that is secreted by tryptophan from the pineal gland into the bloodstream and cerebrospinal fluid. Melatonin plays an important role in regulating the biological clock in humans and has a wide range of antioxidant properties. Melatonin antioxidant mechanisms are directly (through free radical scavenging) or indirectly (by regulating the activity of antioxidant enzymes) involved. Melatonin reduces surgical-related oxidative damage and ischemic reperfusion injury cedera (Jouybar R et al., 2020).

A wide spectrum of immunological functions have been associated with Interleukin 9 (IL-9), including effects on the survival and proliferation of immune cells and parenchyma. Evidence suggests that IL-9 expression can promote tissue repair under inflammatory conditions. However, data on the involvement of IL-9 in renal tissue protection are limited. Xiong (2020) investigated the role of IL-9 in the occurrence of nephropathy in a mouse model (Xiong T et al., 2020).

This study showed that patients with AKI had higher IL-9 than those without AKI both at preinduction (63.3 ± 23.2 vs. 55.7 ± 15.8), during (45.2 ± 11.0 vs. 44.2 ± 9.2) and early ICU (49.6 ± 11.3 vs. 46.2 ± 15.6). There was no statistically significant relationship between IL-9 preinduction (p-value 0.444), during (p-value 0.838), and early ICU (p-value 0.351). Likewise, in the analysis of changes or deltas of IL-9 in patients with AKI had higher IL-9 deltas than those without AKI during duration-preinduction (-18.1 ± 25.8 vs. -11.5 ± 15.8 ), early ICU-preinduction (-13.7 ± 19.7 vs. -9.4 ± 19.0) and early ICU-durante (4.4 ± 11.9 vs. 2.05 ± 16.7). Statistically significant relationship was not seen in delta IL-9 durante-preinduction (p-value 0.518), early ICU-preinduction (p-value 0.622), and early ICU-durante (p-value 0.692).

**CONCLUSION**

From this study it can be concluded that most CABG patients undergoing CPB have AKI. Patients without AKI had higher NGAL results and lower plasma IL-9. Therefore, statistically both cannot be used as predictive biomarkers of the incidence of AKI.

**REFERENCES**


